Patents Assigned to APOGENIX AG
  • Composition comprising a mixture of CD95-Fc isoforms
    Patent number: 9657083
    Abstract: The present invention relates to a composition comprising a mixture of fusion protein isoforms, each fusion protein comprising an extracellular CD95 domain or a functional fragment thereof or an Fc domain or functional fragment thereof, formulations providing such composition in a stable form as well as a method for producing such a composition.
    Type: Grant
    Filed: April 18, 2016
    Date of Patent: May 23, 2017
    Assignee: Apogenix AG
    Inventors: Oliver Hill, Christian Gieffers, Meinolf Thiemann
  • Inhibitors of the CD95 signaling pathway for treatment of MDS
    Patent number: 9540431
    Abstract: The present invention relates to inhibitors of the CD95 signaling pathway for the use in the treatment of Myelodysplastic Syndrom (MDS) wherein the MDS is selected from the IPSS low risk MDS subgroup and/or the IPSS intermediate-1 (int-1) risk MDS subgroup as well as a method for the diagnosis of MDS.
    Type: Grant
    Filed: July 18, 2013
    Date of Patent: January 10, 2017
    Assignee: Apogenix AG
    Inventors: Harald Fricke, Michaela Fontenay, Claudia Kunz
  • CD40L collectin fusion proteins and encoding nucleic acid molecules
    Patent number: 9527897
    Abstract: The present invention refers to a fusion protein comprising a TNF-superfamily (TNFSF) cytokine or a receptor binding domain thereof fused to a collectin trimerization domain, to a nucleic acid molecule encoding the fusion protein, and to a cell comprising the nucleic acid molecule. The fusion protein is present as a trimeric complex or as an oligomer thereof. The fusion protein, the nucleic acid, and the cell is suitable as pharmaceutical composition or for therapeutic, diagnostic and/or research applications.
    Type: Grant
    Filed: December 14, 2015
    Date of Patent: December 27, 2016
    Assignee: Apogenix AG
    Inventors: Oliver Hill, Christian Gieffers, Meinolf Thiemann, Marcus Branschädel
  • Fusion proteins forming trimers
    Patent number: 9469681
    Abstract: The present invention refers to fusion proteins comprising a neck region and carbohydrate recognition domain of a collectin trimerization domain, a linker element and an effector polypeptide. Further the invention refers to a nucleic acid encoding the said fusion protein. The fusion proteins, the nucleic acid, and the cell are suitable as pharmaceutical composition or for therapeutic, diagnostic and/or research applications as described herein.
    Type: Grant
    Filed: January 21, 2014
    Date of Patent: October 18, 2016
    Assignee: APOGENIX AG
    Inventors: Oliver Hill, Marcus Branschaedel, Christian Gieffers, Meinolf Thiemann
  • Shortened CD95-Fc variant fusion proteins, nucleic acids and host cells thereof
    Patent number: 9434783
    Abstract: The present invention relates to an isolated fusion protein comprising an extracellular CD95 domain or a functional fragment thereof and an Fc domain or functional fragment thereof, formulations providing such fusion protein in a stable form as well as a method for producing such a fusion protein.
    Type: Grant
    Filed: July 18, 2013
    Date of Patent: September 6, 2016
    Assignee: APOGENIX AG
    Inventors: Oliver Hill, Christian Gieffers, Meinolf Thiemann
  • Single chain trail fusion polypeptides and encoding nucleic acids
    Patent number: 9359420
    Abstract: The present invention refers to single-chain fusion proteins comprising three soluble TNF superfamily (TNFSF) cytokine domains and nucleic acid molecules encoding these fusion proteins. The fusion proteins are substantially non-aggregating and suitable for therapeutic, diagnostic and/or research applications.
    Type: Grant
    Filed: June 30, 2014
    Date of Patent: June 7, 2016
    Assignee: APOGENIX AG
    Inventors: Oliver Hill, Christian Gieffers, Meinolf Thiemann
  • Single chain CD40L fusion polypeptides
    Patent number: 9340599
    Abstract: The present invention refers to single-chain fusion proteins comprising three soluble TNF superfamily (TNFSF) cytokine domains and nucleic acid molecules encoding these fusion proteins. The fusion proteins are substantially non-aggregating and suitable for therapeutic, diagnostic and/or research applications.
    Type: Grant
    Filed: December 2, 2014
    Date of Patent: May 17, 2016
    Assignee: APOGENIX AG
    Inventors: Oliver Hill, Christian Gieffers, Meinolf Thiemann